The endocannabinoid research line was started as part of a project financed by Top Institute Pharma (TIP), where we studied the role of endocannabinoid (eCB) in signalling processes in the prefrontal cortex (PFC). One of the main findings of that research was that intracellular CB2 receptors in layer 2/3 neurons of the PFC are involved in regulating neuronal excitability.
In a follow-up study (financed by the Dutch Epilepsy Fund) we are now studying the role of the eCB system in epilepsy.
The project has two topics:
(1) the role of the endocannabinoid CB1 receptor in cortical development and epileptogenesis (Focal Cortical Dysplasia) and
(2) CB2 receptors controlling epileptic activity.